Single Vaccine Could Protect Against All Coughs, Colds and Flus

Researchers claim a new nasal spray vaccine could provide broad, durable protection against diverse respiratory threats.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

A new nasal spray vaccine being developed by researchers at Stanford University is claimed to offer protection against a wide range of respiratory illnesses, including coughs, colds, flus, and even some bacterial infections. The vaccine is said to work by 'priming' the immune system to be on 'high alert' and ready to rapidly respond to any invading pathogens, rather than targeting specific viruses. However, the researchers acknowledge there are key differences between the immune systems of mice and humans, and human trials are still needed to determine if the same effects can be achieved.

Why it matters

The development of a 'universal' vaccine that could protect against multiple respiratory diseases is seen as an important potential advancement, especially in the early stages of a new pandemic when a pathogen-specific vaccine may not yet be available. However, the claims about the vaccine's mechanism of action and ability to provide broad protection remain unproven, and there are concerns about potential 'friendly fire' from an overly activated immune system.

The details

The new vaccine approach does not aim to 'train' the immune system to recognize specific pathogens, as traditional vaccines do. Instead, it is designed to keep immune cells in the lungs, called macrophages, on 'high alert' and ready to rapidly respond to any infection. In animal studies, this was shown to reduce the amount of viruses getting into the body by 100 to 1,000 times. The vaccine uses a combination of toll-like receptor agonists to trigger this heightened immune state.

  • The research article describing the vaccine was published in the journal Science on February 19, 2026.
  • The researchers are now planning human trials where a vaccinated person will be deliberately infected to test the vaccine's effectiveness.

The players

Bali Pulendran

A professor of microbiology and immunology at Stanford University who is leading the research on the new vaccine.

Jonathan Ball

A professor of molecular virology at the Liverpool School of Tropical Medicine who expressed caution about the potential for 'friendly fire' from the vaccine's heightened immune response.

Got photos? Submit your photos here. ›

What they’re saying

“It is not known whether the same effect can be achieved in people or how long the immune system would stay in amber alert. There are differences in the immune systems between mice and humans, including our immunity being shaped by decades of infections.”

— Jonathan Ball, Professor of molecular virology (BBC)

“Following infection, vaccinated mice mounted rapid pathogen-specific T cell and antibody responses and formed ectopic lymphoid structures in the lung. These results reveal a class of 'universal vaccines' against diverse respiratory threats.”

— Bali Pulendran, Professor of microbiology and immunology (Science)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This research highlights the ongoing quest for a 'universal' vaccine that could provide broad protection against respiratory illnesses. However, the claims about the vaccine's mechanism and efficacy remain unproven, and there are valid concerns about potential negative impacts from overstimulating the immune system. Further human trials will be needed to determine if this approach is safe and effective in people.